January 13, 2019

San Carlos, Cali.// Atropos Therapeutics, Inc., an early-stage senescence therapeutics discovery company, announced that it was selected as one of the “top 8 ranked companies of the West Coast tech hubs” to present to a panel of early-stage investors at RESI (Redefining Early Stage Investments) San Francisco  2019, which is held during the JP Morgan Healthcare Conference. The panel members were: Lindy Fishburne, Executive Director of Breakout Labs/Thiel Foundation; Melissa Krauth, Managing Partner, ES Ventures; Mike Edelhart, Managing Partner, Joyance Partners; Orrin Ailloni-Charas, MD, Managing Partner, Hermes Life Science Venture Fund; and Ravi Mistry, Member, TiE Angels.

"We are extremely pleased to be recognized by this distinguished group of life-sciences investors and the LSN RESI community," said Tommy Nguyen, MD PHD, CEO and co-founder of Atropos. "Everyone knows that aging-related diseases and resistant cancers remain a huge problem with today's solutions developed piecemeal for individual conditions," explained co-founder Dr. Andrew Koff, PHD. Nguyen further added, "This distinction helps validate our vision to reinvent the therapeutics paradigm using newly discovered small molecule compounds that target the ability to undergo senescence as the underlying mechanism. We look forward to a successful seed financing to support our programs for the next 24 months and generate lead compounds and IP."

Atropos' novel approach to senescence modulator (senomodulator) discovery is focused on high-throughput, -content phenotypic screening of compound libraries and rational drug combinations. The proprietary technology platform called FATES (First ATRX-based Therapeutics Elucidating Senescence) is designed to take advantage of the earliest known molecular marker to show commitment to the irreversible senescence pathway after transient growth arrest. The company is currently conducting preclinical lead selection studies, in order to establish efficacy and safety in in vitro and screening animal models and to support moving into IND-enabling studies for human clinical studies for disease indications in aging and resistant cancers. Lead Selection phase is expected to be complete by early 2020. Separately, the company plans to discover senosuppressor compounds with lower apoptosis and toxicity potential for testing in primary skin and other primary tissues.  Since starting in March 2018, the company has secured significant funding from the NIH’s (National Institutes of Health) NIA (National Institute of Aging), filed its first provisional patent application for the wholly owned technology platform, and established a company lab headquarters at MBC Labs- San Carlos. The company is currently contemplating a seed investor round during the first half of the year to accomplish several corporate goals: building the R&D team, adding industry and small molecule expertise, and progressing its anti-aging program, cancer discovery program, and skin health program.

The RESI conference is staged by Life Science Nation (LSN).


September 11, 2019

A joint venture between Atropos and Atomwise will discover and develop anticancer agents using senescence assay and AI technologies

SAN FRANCISCO & BELMONT, Calif.--(BUSINESS WIRE)-- Atomwise Inc., a leader in artificial intelligence (AI) for drug discovery, and Atropos Therapeutics, Inc., a senescence platform discovery company, announced today that they will launch a joint venture company to discover and advance a pipeline of compounds for promising discovery targets for the treatment of cancer.

Cellular senescence is a regulated biological process by which cells stop dividing irreversibly and is a normal part of aging. However, the failure and induction of senescence also have an important role in the development and treatment of cancers, respectively. Compounds that modulate senescence have enormous potential as novel anticancer agents. Atropos and Atomwise will use their platform technologies and complementary capabilities to perform screens to identify and develop novel compounds for undisclosed targets that modulate cellular senescence and evaluate their potential for development as safe and effective drugs for the treatment of cancer.

“We are excited to be embarking on this joint enterprise with Atomwise. We value the innovation that the two respective teams bring and look forward to working together toward new and better therapies for cancer patients,” said Tommy Nguyen, M.D., Ph.D., CEO and Co-Founder of Atropos.

“This partnership with Atropos is an opportunity to ultimately provide patients with a fundamentally different class of drugs,” said Abraham Heifets, Ph.D., CEO and Co-Founder of Atomwise. “We are excited to apply our technology to targets that are considered to be intractable and advance the discovery and development of drugs that modulate cellular senescence to treat cancer.”

Under the terms of the agreement, the joint venture company will have access to Atropos’ and Atomwise’s cutting-edge technology and expertise in aging, cancer biology, computational and medicinal chemistry, and artificial intelligence for drug discovery.

About Atropos Therapeutics
Founded in 2018, Atropos is a biotechnology platform company focused on the discovery, development, and commercialization of therapies targeting the formation of senescent cells. The company is leveraging unexploited insights in senescence biology to discover agents and modalities. This disruptive approach to “aging” disorders and cancer, targets that which is common to these diseases, the stress-induced accumulation of the senescent cell in various tissues. For more information, please visit

About Atomwise
Atomwise Inc. invented the first deep learning AI technology for structure-based small molecule drug discovery. Created in 2012, today Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as hundreds of universities and hospitals in 19 countries. Atomwise has raised over $50 million from leading venture capital firms to support the development and application of its AI technology. Learn more at or follow @AtomwiseInc.

View source version on


Atropos Therapeutics
Ethan Than

Sara Dunn

©2018 by Atropos Therapeutics Inc.. Proudly created with